Renae Quale

University of Wisconsin Carbone Cancer Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Jacquelyn A. Hank

University of Wisconsin–Madison

Paul M. Sondel

University of Wisconsin–Madison

KyungMann Kim

University of Wisconsin–Madison

Mark R. Albertini

University of Wisconsin–Madison

Cindy Zuleger

University of Wisconsin Carbone Cancer Center

Erik A. Ranheim

University of Wisconsin–Madison

Richard K. Yang

The University of Texas MD Anderson Cancer Center

Zachary S. Morris

University of Wisconsin–Madison

Jun S. Wei

First Affiliated Hospital of Wannan Medical College

Sivasish Sindiri

National Cancer Institute

Cooperative Institutions

University of Wisconsin–Madison

University of Wisconsin Carbone Cancer Center

National Cancer Institute

UW Health University Hospital

Highland Community College - Illinois

Center for Cancer Research

National Institutes of Health

Madison Group (United States)

University of Wisconsin Health

St. Jude Children's Research Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Supplemental Figure SF-04 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Richard K. Yang Igor B. Kuznetsov Erik A. Ranheim Jun S. Wei Sivasish Sindiri

Hu14.18-IL2 Treatment Improves Direct Positive Correlations between Myeloid and Lymphoid Cells as indicated by ssGSEA Signatures

10.1158/1078-0432.22476410.v1

Cite

Citations (0)

Supplemental Figure SF-09 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Richard K. Yang Igor B. Kuznetsov Erik A. Ranheim Jun S. Wei Sivasish Sindiri

Some FcR Expression Prognosticates Favorable Survival in Group A, But Not Group B

10.1158/1078-0432.22476395.v1

Cite

Citations (0)

Supplemental Figure SF-15 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Richard K. Yang Igor B. Kuznetsov Erik A. Ranheim Jun S. Wei Sivasish Sindiri

Expanded Pathway-Level Enrichment Analysis of Gene Sets Whose Expression Correlates with Overall Survival in Group A Patients

10.1158/1078-0432.22476377.v1

Cite

Citations (0)

Supplemental Figure SF-03 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Richard K. Yang Igor B. Kuznetsov Erik A. Ranheim Jun S. Wei Sivasish Sindiri

Hu14.18-IL2 Treatment Improves Direct Positive Correlations between Myeloid and Lymphoid Cells as indicated by ssGSEA Signatures

10.1158/1078-0432.22476413

Cite

Citations (0)

Supplemental Figure SF-08 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Richard K. Yang Igor B. Kuznetsov Erik A. Ranheim Jun S. Wei Sivasish Sindiri

Killer Immunoglobulin-Like Receptors (KIRs) and Killer Cell Lectin-Like Receptors (KLRs) Prognosticate Favorable Survival in Group A, But Not Group B

10.1158/1078-0432.22476398

Cite

Citations (0)

Supplemental Figure SF-14 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Richard K. Yang Igor B. Kuznetsov Erik A. Ranheim Jun S. Wei Sivasish Sindiri

Compared to Treatment Naïve Tumors (Group B and 2 untreated patients), IC treated Tumors (Group A) Demonstrate Increased Amounts of Growth Factor Expression, Oncogene and Immune Gene Expression, but Decreased Amounts of Melanoma Related Genes

10.1158/1078-0432.22476380.v1

Cite

Citations (0)

Supplemental Figure SF-04 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Richard K. Yang Igor B. Kuznetsov Erik A. Ranheim Jun S. Wei Sivasish Sindiri

Hu14.18-IL2 Treatment Improves Direct Positive Correlations between Myeloid and Lymphoid Cells as indicated by ssGSEA Signatures

10.1158/1078-0432.22476410

Cite

Citations (0)

Supplemental Methods and Figure Legends from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Richard K. Yang Igor B. Kuznetsov Erik A. Ranheim Jun S. Wei Sivasish Sindiri

Supplemental Methods and Figure Legends

10.1158/1078-0432.22476371

Cite

Citations (0)

Supplemental Figure SF-14 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Richard K. Yang Igor B. Kuznetsov Erik A. Ranheim Jun S. Wei Sivasish Sindiri

10.1158/1078-0432.22476380

Cite

Citations (0)

Supplemental Figure SF-15 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Richard K. Yang Igor B. Kuznetsov Erik A. Ranheim Jun S. Wei Sivasish Sindiri

Expanded Pathway-Level Enrichment Analysis of Gene Sets Whose Expression Correlates with Overall Survival in Group A Patients

10.1158/1078-0432.22476377

Cite

Citations (0)